MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy
{{output}}
Purpose: Describe the design and rationale of the MAGIC (ClinicalTrials.gov identifier, NCT05681884) trial assessing change in retinal non-perfusion (RNP) among eyes with non-proliferative diabetic retinopathy (NPDR) in sham and ... ...
